ArticlePloS one2025
Proinflammatory gene and protein expression alterations in human limbal aniridia fibroblasts.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aniridia-associated keratopathy: Clinical and molecular mechanisms of disease progression and emerging therapeutic targets.Acta ophthalmologica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aniridia-associated keratopathy (AAK) results from the paired box 6 (PAX6) gene haploinsufficiency, leading to depletion of limbal epithelial stem cells, persistent inflammation and a gradual loss of vision. Although fibroblasts are acknowledged as sentinel cells initiating corneal inflammation, their contribution in the chronic inflammatory state of AAK remains unexplored. Our study aims to compare PAX6 and inflammatory cytokine expression in limbal fibroblast cells (LFCs) of corneal donors and aniridia patients (AN-LFCs). Furthermore, we subjected LFCs and AN-LFCs to LPS and cobalt chloride (CoCl2), to investigate specific inflammatory reactions. Following isolation and culture, primary LFCs (n = 7) and AN-LFCs (n = 7) were subjected to a 24-hour treatment with E. coli LPS or a 48-hour exposure to CoCl2 as a chemical oxidative stress (OS) inducer. Subsequently, PAX6 as well as IL-1β, IL-6, TNF-α, and VEGF gene expression was examined by qPCR. Corresponding protein levels were assessed by ELISA from the cell culture supernatants. AN-LFCs exhibited similar PAX6 mRNA levels as normal LFCs (p ≥ 0.38). Notably, LPS treatment (p ≤ 0.02), but not CoCl2, significantly enhanced PAX6 expression. Untreated AN-LFCs showed higher IL-6 mRNA (p = 0.002) and protein levels (p = 0.009) but lower TNF-α protein expression (p = 0.016) than LFCs. When exposed to LPS, AN-LFCs exhibited higher IL-1β mRNA (p = 0.0008), as well as IL-6 protein expression (p = 0.029) than normal LFCs. Under OS, an elevated IL-6 protein (p = 0.010) was observed in AN-LFCs compared to LFCs. Our study revealed inflammatory gene and protein expression alterations in AN-LFCs, that could be involved in the stromal niche perturbations seen in AAK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.